%0 Journal Article
%T Novel oral anticoagulants for acute coronary syndrome
%A April Robinson
%A Delilah McCarty
%A Janine Douglas
%J Archive of "Therapeutic Advances in Cardiovascular Disease".
%D 2017
%R 10.1177/1753944716671484
%X Acute coronary syndrome (ACS) is a cardiovascular condition with a multifactorial pathophysiology that includes atherosclerotic plaques, platelet activation and thrombin production, among others. Thrombin production and the prothrombotic state of ACS patients have provided a role for anticoagulants to treat patients during the acute event and has led to subsequent research for the post-acute state. Warfarin has an indication for ACS, however, it is restricted to specific patients and many factors limit its use. Therefore, novel oral anticoagulants (NOACs) are being explored for ACS. Limitations for the use of NOACs in ACS are centered on the increased risk of bleeding that occurs when these agents are added to the current standard of care with dual antiplatelet therapy. Rivaroxaban is the only NOAC that has achieved approval in Europe for this indication with none of the NOAC currently approved in the US for use in ACS. Ongoing studies for rivaroxaban and apixaban may provide evidence to further clarify the place in therapy for NOAC agents in ACS management
%K acute coronary syndrome
%K novel oral anticoagulants
%K thrombin
%K anticoagulation
%K antiplatelet
%K apixaban
%K rivaroxaban
%K edoxaban
%K dabigatran
%K warfarin
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933556/